Dexcom Upgraded to Buy on Forecasted Gross Margin Increase through 2026
Benchmark upgraded Dexcom to Buy, highlighting potential margin expansion as G7 shipments scale and factory cost efficiencies improve. The firm noted operational leverage could boost gross margins by several percentage points through 2026.
1. Benchmark Upgrades Dexcom to Buy
Benchmark raised its rating on Dexcom to Buy, citing expectations for improved profitability as the company scales its next-generation G7 continuous glucose monitoring system.
2. Drivers of Margin Expansion
The firm highlighted operational leverage from higher G7 shipments and efficiency gains in manufacturing that could expand gross margins by several percentage points over the next year.
3. Financial and Valuation Implications
Stronger margins could boost adjusted EBITDA and free cash flow, potentially justifying a higher valuation multiple and supporting upside for Dexcom's share price.